Plain-English translation of NCT02579811 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kidney cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied , a targeted therapy medication, given on a customized dose schedule for people with advanced kidney cancer whose disease had progressed after immunotherapy treatment. The researchers wanted to see whether adjusting the dose based on how well patients tolerated the medication could improve how long patients lived without their cancer growing. The study enrolled about 40 patients to evaluate whether this personalized approach worked better than standard dosing.
Many patients with advanced kidney cancer benefit from immunotherapy at first, but eventually their cancer stops responding to it. This trial was designed to find out whether a new dosing strategy for this targeted medication could help patients whose cancer had become resistant to immunotherapy, giving them another effective treatment option.
Participants took by mouth, starting at a standard dose that could be adjusted up or down based on side effects they experienced. The medication continued until their cancer progressed, at which point doctors could try increasing the dose again if they thought it might help. Participants attended scheduled clinic visits for blood tests, imaging scans to measure their tumors, and monitoring of side effects throughout the trial period.
AI-generated summary from trial data · Oct 11, 2026 · Not medical advice
United States